Navigation Links
WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
Date:8/9/2009

SHANGHAI, Aug. 9 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on August 7, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

At the meeting, WuXi PharmaTech shareholders approved the re-election of incumbent Class B directors Xuesong Leng, Zhaohui Zhang, and Ning Zhao, each to serve a three-year term.

In addition, the WuXi shareholders approved an amendment to the Company's Memorandum of Articles and Association that revises Article 82 so that it no longer requires a Special Resolution be obtained for an office of a Director to be considered vacated.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

    WuXi PharmaTech (Cayman) Inc.
     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: ir@wuxiapptec.com

     Stephanie Liu (for the media)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
2. WuXi PharmaTech Receives Award from BASF
3. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
4. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
5. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
6. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
7. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
8. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
9. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
10. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
11. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), ... , today announced that its board of directors has amended its ... from March 27, 2017 to March 27, 2018. The amendment was not ... Biotech Ltd. ... Sinovac Biotech Ltd. is a China -based ...
(Date:3/24/2017)... -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with ... today announced participation at the following conferences: ... Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at the ... York, NY . Agenus will participate in three ... Robert B. Stein , M.D., Ph.D., President, R&D ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... The Global Market for Bioproducts Should Reach $714.6 Billion by ... 8.9%, This research report quantifies the two ... segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite materials, ...
(Date:3/23/2017)... LOUISVILLE, Colo. , March 23, 2017  GlobeImmune, ... purchase agreement for the sale of 12,835,490 shares of ... the  NantWorks  ecosystem of companies. In connection with the sale ... GlobeImmune $100,000 in cash and issue to GlobeImmune 200,000 ... common stock. "We are pleased to ...
Breaking Biology Technology:
(Date:3/16/2017)... 2017 - Against identity fraud with DERMALOG solutions "Made in Germany "  ... ... project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution against ... ...
(Date:3/7/2017)... March 7, 2017 Brandwatch , the leading social ... The Prince,s Trust to uncover insights to support its reporting, ... The UK,s leading youth charity will be using Brandwatch ... and get a better understanding of the topics and issues that ... ...
(Date:3/2/2017)... 2017 Summary This report provides ... KGaA and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
Breaking Biology News(10 mins):